Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and pressures. Learn why MRK stock is a buy.

Rahway, New Jersey-based Merck & Co., Inc. (MRK) operates as a healthcare company worldwide. Valued at $256.4 billion by market cap, the company delivers health solutions through its prescription ...

MRK Stock Price, Valuation & Estimates Merck’s shares have lost 15.3% in the past year compared witha decline of 3.9% for the industry. The stock has also underperformed the sector and the S&P ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its ...

Merck and S&P 500 Performance During 2007-08 Crisis. MRK stock declined from $52 in September 2007 (pre-crisis peak) to around $24 in March 2009 (as the markets bottomed out), implying it lost ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck & Co reports Q1 earnings on Thursday with EPS of $2.14 and revenue of $15.33B expected. Despite a 38.04% drop in stock over past year, analysts see ~30% upside potential.